$CCEL
CRYO CELL INTERNATIONAL INC

2020 Q4 Form 10-K Financial Statement

#000156459021009945 Filed on March 01, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2019 Q4 2019 Q2
Revenue $7.541M $7.970M $8.128M
YoY Change -5.39% -7.26% 24.56%
Cost Of Revenue $2.313M $2.352M $2.628M
YoY Change -1.65% -12.06% 47.89%
Gross Profit $5.227M $5.618M $5.500M
YoY Change -6.95% -5.08% 15.82%
Gross Profit Margin 69.32% 70.49% 67.66%
Selling, General & Admin $3.490M $3.942M $3.648M
YoY Change -11.46% -4.32% 3.25%
% of Gross Profit 66.76% 70.16% 66.33%
Research & Development $7.060K $16.86K $4.957K
YoY Change -58.13% -37.37% -83.07%
% of Gross Profit 0.14% 0.3% 0.09%
Depreciation & Amortization $87.60K $96.85K $103.4K
YoY Change -9.55% -6.02% 72.38%
% of Gross Profit 1.68% 1.72% 1.88%
Operating Expenses $1.763M $4.005M $3.653M
YoY Change -55.99% -4.68% 2.54%
Operating Profit $3.464M $1.613M $496.6K
YoY Change 114.81% -6.07% -56.81%
Interest Expense -$349.6K -$351.6K $424.3K
YoY Change -0.6% -36.23% 39.52%
% of Operating Profit -10.09% -21.8% 85.44%
Other Income/Expense, Net $20.00 $30.14K -$391.9K
YoY Change -99.93% -176.81% 33.18%
Pretax Income $1.831M $1.291M $104.6K
YoY Change 41.77% -16.24% -87.77%
Income Tax $630.8K $446.3K $50.94K
% Of Pretax Income 34.46% 34.56% 48.7%
Net Earnings $1.200M $845.0K $53.67K
YoY Change 42.0% -5.14% -90.05%
Net Earnings / Revenue 15.91% 10.6% 0.66%
Basic Earnings Per Share $0.01
Diluted Earnings Per Share $147.2K $101.1K $0.01
COMMON SHARES
Basic Shares Outstanding 7.546M 7.803M 7.803M
Diluted Shares Outstanding 8.421M

Balance Sheet

Concept 2020 Q4 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.17M $7.445M $7.308M
YoY Change 50.01% 7.65% 2.79%
Cash & Equivalents $10.36M $6.541M $6.469M
Short-Term Investments $807.0K $904.1K $839.8K
Other Short-Term Assets $244.7K $260.4K $278.1K
YoY Change -6.03% 2.33% 46.07%
Inventory $927.3K $1.085M $1.046M
Prepaid Expenses $611.6K $500.3K $610.6K
Receivables $6.323M $6.097M $5.867M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $18.56M $15.39M $15.00M
YoY Change 20.59% 4.25% 15.07%
LONG-TERM ASSETS
Property, Plant & Equipment $1.641M $1.846M $1.748M
YoY Change -11.14% 23.64% 68.37%
Goodwill $1.941M $1.941M $1.941M
YoY Change 0.0% 0.0%
Intangibles $1.182M $1.249M $1.288M
YoY Change -5.42% -6.86% 218.6%
Long-Term Investments $308.0K $308.0K $308.0K
YoY Change 0.0% 0.0%
Other Assets $26.00M $25.65M $24.14M
YoY Change 1.37% -1.85% 196.37%
Total Long-Term Assets $27.64M $27.50M $25.89M
YoY Change 0.53% -2.23% 181.91%
TOTAL ASSETS
Total Short-Term Assets $18.56M $15.39M $15.00M
Total Long-Term Assets $27.64M $27.50M $25.89M
Total Assets $46.20M $42.89M $40.89M
YoY Change 7.73% 0.0% 84.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $957.4K $1.369M $1.029M
YoY Change -30.07% 8.52% -7.56%
Accrued Expenses $2.898M $2.085M $965.0K
YoY Change 38.99% -22.85% -55.78%
Deferred Revenue $9.183M $8.875M $8.365M
YoY Change 3.47% 6.09%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $3.100M $3.100M
YoY Change 0.0% 0.0% 55.0%
Total Short-Term Liabilities $16.41M $15.43M $13.61M
YoY Change 6.39% 0.0% 6.35%
LONG-TERM LIABILITIES
Long-Term Debt $2.841M $5.856M $1.425M
YoY Change -51.48% 310.96% 0.0%
Other Long-Term Liabilities $32.45M $34.41M $35.37M
YoY Change -5.69% -4.07% 50.38%
Total Long-Term Liabilities $32.45M $34.41M $36.80M
YoY Change -5.69% -7.73% 47.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.41M $15.43M $13.61M
Total Long-Term Liabilities $32.45M $34.41M $36.80M
Total Liabilities $48.87M $49.84M $48.98M
YoY Change -1.95% -2.84% 34.86%
SHAREHOLDERS EQUITY
Retained Earnings -$18.82M -$22.44M -$24.41M
YoY Change -16.15% -11.39% -7.78%
Common Stock $36.72M $36.05M $35.88M
YoY Change 1.84% 1.13% 12.93%
Preferred Stock
YoY Change
Treasury Stock (at cost) $20.56M $20.56M $19.57M
YoY Change 0.0% 5.07% 0.0%
Treasury Stock Shares $6.094M $6.094M $5.801M
Shareholders Equity -$2.665M -$6.953M -$8.094M
YoY Change
Total Liabilities & Shareholders Equity $46.20M $42.89M $40.89M
YoY Change 7.73% 1.17% 84.02%

Cashflow Statement

Concept 2020 Q4 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income $1.200M $845.0K $53.67K
YoY Change 42.0% -5.14% -90.05%
Depreciation, Depletion And Amortization $87.60K $96.85K $103.4K
YoY Change -9.55% -6.02% 72.38%
Cash From Operating Activities $2.977M $1.199M $527.7K
YoY Change 148.3% 42.04% 1658.93%
INVESTING ACTIVITIES
Capital Expenditures -$47.56K -$155.0K -$359.8K
YoY Change -69.31% 309.3%
Acquisitions
YoY Change
Other Investing Activities $99.36K -$29.36K
YoY Change -438.42% -5.47%
Cash From Investing Activities $51.80K -$184.3K -$359.8K
YoY Change -128.1% 167.4% -3697.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -775.0K -1.812M -775.0K
YoY Change -57.24% 2.1% 55.0%
NET CHANGE
Cash From Operating Activities 2.977M 1.199M 527.7K
Cash From Investing Activities 51.80K -184.3K -359.8K
Cash From Financing Activities -775.0K -1.812M -775.0K
Net Change In Cash 2.254M -797.7K -607.1K
YoY Change -382.49% -20.22% 31.98%
FREE CASH FLOW
Cash From Operating Activities $2.977M $1.199M $527.7K
Capital Expenditures -$47.56K -$155.0K -$359.8K
Free Cash Flow $3.024M $1.354M $887.5K
YoY Change 123.4% 53.52% 2858.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1800
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
CY2020 dei City Area Code
CityAreaCode
813
CY2020 dei Local Phone Number
LocalPhoneNumber
749-2100
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7570913
CY2020Q2 dei Entity Public Float
EntityPublicFloat
29618382
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Security Exchange Name
SecurityExchangeName
NONE
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10361125
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6541037
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
88476
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
904053
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6097331
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
611627
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
500260
CY2020Q4 us-gaap Inventory Net
InventoryNet
927318
CY2019Q4 us-gaap Inventory Net
InventoryNet
1084533
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
244696
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
260397
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18556202
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32450608
CY2020Q4 us-gaap Liabilities
Liabilities
48865229
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
136336
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36581600
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18819714
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2665135
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46200094
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2781668
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2584091
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13633638
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7545613
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7510884
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
CY2020 dei Entity File Number
EntityFileNumber
000-23386
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd,
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23632
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16414621
CY2019Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1425000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9183450
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34409582
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
27200910
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1509852
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2841214
CY2019Q4 us-gaap Liabilities
Liabilities
49839011
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13598909
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31147593
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9657442
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14294233
CY2019Q4 us-gaap Assets Current
AssetsCurrent
15387611
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1640774
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1846467
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1181588
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1249254
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11064034
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12646000
CY2020Q4 us-gaap Goodwill
Goodwill
1941411
CY2019Q4 us-gaap Goodwill
Goodwill
1941411
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
10363967
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9079994
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
299089
CY2020Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
495029
CY2019Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
427423
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26003118
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25652082
CY2020Q4 us-gaap Assets
Assets
46200094
CY2019Q4 us-gaap Assets
Assets
42886160
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
957390
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1369111
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2898211
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2085180
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275570
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8875138
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15429429
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
23633373
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3495057
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5856152
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31816571
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10036175
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14891462
CY2020 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1284238
CY2019 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2020 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1940205
CY2019 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-742918
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23851
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30145
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
166437
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
206238
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
23485996
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
26753865
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
7661597
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
5062706
CY2020 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-8130
CY2019 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
28364
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
773
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3791
CY2020 us-gaap Interest Expense
InterestExpense
1544017
CY2019 us-gaap Interest Expense
InterestExpense
1703446
CY2020 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-1070900
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2622274
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1671291
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5039323
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3391415
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1414727
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1100641
CY2020 us-gaap Net Income Loss
NetIncomeLoss
3624596
CY2019 us-gaap Net Income Loss
NetIncomeLoss
2290774
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.48
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7544494
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7794828
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8140180
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8412414
CY2020 us-gaap Profit Loss
ProfitLoss
3624596
CY2019 us-gaap Profit Loss
ProfitLoss
2290774
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
372289
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
401311
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1032
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
622120
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
397770
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
602965
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
767128
CY2020 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1283973
CY2019 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1517289
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
85062
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
112642
CY2020 ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
263686
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
828594
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
997124
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
111367
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
38445
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-454943
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
27423
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-15701
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
5932
CY2020 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
67606
CY2019 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-15696
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-411721
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
107458
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1092131
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-599200
CY2020 ccel Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-263573
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3875849
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3825996
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8466603
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6294843
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
99962
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
662295
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
350000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
807447
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
357485
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-662295
CY2020 ccel Payments For Extinguishment Of Revenue Sharing Agreements
PaymentsForExtinguishmentOfRevenueSharingAgreements
1900000
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
992244
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3100000
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4100000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3820088
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
501004
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6040033
CY2020 ccel Operating Leaseright Of Useasset Recorded Due To Adoption Of Asc842
OperatingLeaserightOfUseassetRecordedDueToAdoptionOfAsc842
562775
CY2020 ccel Operating Lease Liability Recorded Due To Adoption Of Asc842
OperatingLeaseLiabilityRecordedDueToAdoptionOfAsc842
562775
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5700
CY2020 ccel Payment Of Earnout
PaymentOfEarnout
45000
CY2019 ccel Payment Of Earnout
PaymentOfEarnout
45000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5004000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5131544
CY2019Q4 ccel Cumulative Effect Adjustment Due To Adoption Of Accounting Standard Update
CumulativeEffectAdjustmentDueToAdoptionOfAccountingStandardUpdate
-340984
CY2019 ccel Cumulative Effect On Retained Earnings Tax
CumulativeEffectOnRetainedEarningsTax
94192
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-8908298
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5700
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
397770
CY2019 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
992244
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
622120
CY2020 ccel Covid19
Covid19
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Palatino Linotype;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 17 &#8211; COVID-19</p> <p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-family:Palatino Linotype;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (&#8220;COVID-19&#8221;) outbreak.&#160; The Company faces various risks related to health epidemics, pandemics and similar outbreaks, including the global outbreak of COVID-19.&nbsp;&nbsp;The Company believes it has taken appropriate steps to minimize the risk to our employees and to maintain normal business operations and continues to actively monitor the global outbreak and spread of COVID-19 and continues to take steps to mitigate the potential risks to us posed by its spread and related circumstances and impacts.&nbsp;&nbsp;Due to the change in consumer buying patterns as a result of COVID-19, the Company has experienced a decline in new client sales resulting in a decrease in revenues in fiscal 2020 compared to fiscal 2019.&nbsp;&nbsp;While the ultimate health and economic impact of COVID-19 remains highly uncertain, we expect that our business operations and results of operations, including our net sales, earnings and cash flows, may continue to be impacted by decreases in new client sales.&nbsp;&nbsp;We cannot predict the timing and speed of the recovery, and any delay in the recovery could significantly impact our future results.&nbsp;&nbsp;</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Palatino Linotype;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risks</p> <p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-family:Palatino Linotype;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit.&nbsp;&nbsp;The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk.&nbsp;&nbsp;The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC).&nbsp;&nbsp;The Company believes these are conservative investments with a low risk for any loss of principal.&nbsp;&nbsp;The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.</p> <p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-family:Palatino Linotype;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on one supplier for the source of its collection kits, a critical component of the umbilical cord blood stem cell collection process.&nbsp;&nbsp;However, the Company believes that alternative sources of supply are available.</p> <p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-family:Palatino Linotype;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units.&#160; However, the Company believes that alternative sources of supply and manufacturing are available.</p> <p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-family:Palatino Linotype;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for transplant.</p> <p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-family:Palatino Linotype;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal 2020 and 2019, there were no concentration of risks.</p>
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Palatino Linotype;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-family:Palatino Linotype;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2020 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Palatino Linotype;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Product Warranty and Cryo-Cell Cares<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Program</p> <p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-family:Palatino Linotype;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions.&nbsp;&nbsp;Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients.&nbsp;&nbsp;Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, PrepaCyte CB.&nbsp;&nbsp;The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company.&nbsp;&nbsp;The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. </p> <p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-family:Palatino Linotype;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer.&nbsp;&nbsp;Upon the adoption of ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits at November 30, 2019. &nbsp;&nbsp;At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</p>
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2020 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
The Company depends on one supplier for the source of its collection kits
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
36384360
CY2020Q4 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9183450
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2020 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
49609
CY2019 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
35300
CY2018Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
329231
CY2018Q4 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
66533
CY2020 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
89471
CY2019 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
87518
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
466141
CY2019Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
329231
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5867335
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8365284
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20317231
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
398535
CY2020 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
89471
CY2020 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
21865
CY2020 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
38379247
CY2020 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
38153618
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
32508511
CY2020 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
21237546
CY2020 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
17361697
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36384360
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
807000
CY2019 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020 us-gaap Advertising Expense
AdvertisingExpense
845454
CY2019 us-gaap Advertising Expense
AdvertisingExpense
981448
CY2019Q1 ccel Cumulative Effect Adjustment From Accumulated Other Comprehensive Income To Retained Earnings
CumulativeEffectAdjustmentFromAccumulatedOtherComprehensiveIncomeToRetainedEarnings
341000
CY2020 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-8000
CY2019 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
28000
CY2020 ccel Loss On Cash Liquidating Distribution
LossOnCashLiquidatingDistribution
76000
CY2019 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
112642
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
92000
CY2020Q4 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2020 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
85062
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
595686
CY2019 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
617586
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
622000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
398000
CY2020Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1284238
CY2019Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2020Q4 ccel Inventory Collection Kits
InventoryCollectionKits
33006
CY2019Q4 ccel Inventory Collection Kits
InventoryCollectionKits
44453
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2020Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
11991352
CY2019Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
13730533
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1181588
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1249254
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
67667
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
67667
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
67667
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
67667
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
57980
CY2020Q4 ccel Finite Lived Intangible Assets Amortization Expense Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseThereafter
852940
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68000
CY2020Q4 us-gaap Notes Payable
NotesPayable
6008433
CY2019Q4 us-gaap Notes Payable
NotesPayable
9108433
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
67219
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
152281
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
5941214
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
8956152
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
3100000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2908433
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
310364
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
646744
CY2020 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
395426
CY2019 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
759386
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2264848
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
756688
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
308803
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
751848
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
346460
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9029333
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8963178
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7388559
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7116711
CY2020 us-gaap Depreciation
Depreciation
305000
CY2019 us-gaap Depreciation
Depreciation
309000
CY2020 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
206000
CY2019 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
195000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
47729
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
115000
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
606828
CY2019Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
513108
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
779444
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
950300
CY2020Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
504306
CY2019Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
330726
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
959904
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
176046
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1757000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1637000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
598000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
769000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
68000
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
108000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2423000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2514000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-847000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1106000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-161000
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-307000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1008000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1413000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
7024000
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
6256000
CY2020Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1209000
CY2019Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1224000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
100000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
82000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1895000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1589000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
567000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
411000
CY2020Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
483000
CY2019Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
450000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
19000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
18000
CY2020Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1482000
CY2019Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1095000
CY2020Q4 ccel Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
81000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12860000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11125000
CY2020Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
134000
CY2019Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
117000
CY2020Q4 ccel Deferred Tax Assets Liabilities Tax Credit Carryforwards And Net Operating Losses
DeferredTaxAssetsLiabilitiesTaxCreditCarryforwardsAndNetOperatingLosses
-782000
CY2019Q4 ccel Deferred Tax Assets Liabilities Tax Credit Carryforwards And Net Operating Losses
DeferredTaxAssetsLiabilitiesTaxCreditCarryforwardsAndNetOperatingLosses
-282000
CY2020Q4 ccel Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
81000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
997000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
399000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1499000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1646000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
10364000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
9080000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-147528
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
12158
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1061885
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
733198
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
282514
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0010
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0135
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0310
CY2020 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.0135
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
220527
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
6870
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
26330
CY2020 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
55372
CY2019 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
76775
CY2020 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
80692
CY2019 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
12375
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
74922
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
19278
CY2020 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
68102
CY2019 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
108150
CY2020 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
68102
CY2019 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
108150
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0559
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0632
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0292
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0035
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0014
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0075
CY2020 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.0110
CY2019 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.0220
CY2020 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
0.0160
CY2019 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
0.0035
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0147
CY2019 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.0310
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2798
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3087
CY2020 ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50
CY2020 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
1877000
CY2019 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
2801000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.66
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.02
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1174943
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y5M1D
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.72
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1081563
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
3.37
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
125234
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
105169
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
137023
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
93380
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.70
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.70
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.65
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2020 and the remaining 1/3 on November 30, 2021.
CY2004Q2 ccel Operating Lease Area Of Facility
OperatingLeaseAreaOfFacility
17600
CY2004Q2 ccel Operating Lease Period
OperatingLeasePeriod
P10Y
CY2018Q3 ccel Extended Operating Lease Area Of Facility
ExtendedOperatingLeaseAreaOfFacility
17600
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
318587
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
322984
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
18744
CY2020 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
224928
CY2020 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
179000
CY2019 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
205000
CY2020 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
974276
CY2019 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
832587
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
CY2020 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
299202
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
284847
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
23737
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9382
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y29D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
278788
CY2020Q2 us-gaap Line Of Credit
LineOfCredit
350000
CY2020Q2 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000

Files In Submission

Name View Source Status
0001564590-21-009945-index-headers.html Edgar Link pending
0001564590-21-009945-index.html Edgar Link pending
0001564590-21-009945.txt Edgar Link pending
0001564590-21-009945-xbrl.zip Edgar Link pending
ccel-10k_20201130.htm Edgar Link pending
ccel-20201130.xml Edgar Link completed
ccel-20201130.xsd Edgar Link pending
ccel-20201130_cal.xml Edgar Link unprocessable
ccel-20201130_def.xml Edgar Link unprocessable
ccel-20201130_lab.xml Edgar Link unprocessable
ccel-20201130_pre.xml Edgar Link unprocessable
ccel-ex311_9.htm Edgar Link pending
ccel-ex312_8.htm Edgar Link pending
ccel-ex313_6.htm Edgar Link pending
ccel-ex321_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gwgp4s5jytm3000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending